Active Filter(s):
Details:
The combined company will more efficiently conduct clinical research and development of their promising pipeline of product candidates in organ fibrosis and inflammatory diseases, including F351 (hydronidone) for liver fibrosis.
Lead Product(s): Hydronidone
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: F351
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Beijing Continent Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger October 30, 2023